Donato A Di Monte

List of Publications by Year
in descending order

132 papers	13,283 citations	15504 65 h-index	22166 113 g-index
141 all docs	141 docs citations	141 times ranked	11539 citing authors

#	Article	IF	Citations
1	Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat. Neurobiology of Disease, 2002, 10, 119-127.	4.4	706
2	Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo. Neuron, 2003, 37, 899-909.	8.1	594
3	The Herbicide Paraquat Causes Up-regulation and Aggregation of Î±-Synuclein in Mice. Journal of Biological Chemistry, 2002, 277, 1641-1644.	3.4	566
4	Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Archives of Biochemistry and Biophysics, 1984, 235, 334-342.	3.0	409
5	Menadione-induced cytotoxicity is associated with protein thiol oxidation and alteration in intracellular Ca2+ homeostasis. Archives of Biochemistry and Biophysics, 1984, 235, 343-350.	3.0	372
6	Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration. Journal of Neuroscience, 2007, 27, 8138-8148.	3.6	346
7	The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurology, The, 2003, 2, 531-538.	10.2	320
8	Nuclear Localization of Î±-Synuclein and Its Interaction with Histonesâ€. Biochemistry, 2003, 42, 8465-8471.	2.5	299
9	Lysosomal Degradation of Î±-Synuclein in Vivo. Journal of Biological Chemistry, 2010, 285, 13621-13629.	3.4	298
10	Lack of Nigral Pathology in Transgenic Mice Expressing Human Î±-Synuclein Driven by the Tyrosine Hydroxylase Promoter. Neurobiology of Disease, 2001, 8, 535-539.	4.4	273
11	Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. European Journal of Neuroscience, 2003, 18, 589-600.	2.6	260
12	Behavioral and Neurochemical Effects of Wild-Type and Mutated Human Î±-Synuclein in Transgenic Mice. Experimental Neurology, 2002, 175, 35-48.	4.1	255
13	MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology. PLoS ONE, 2008, 3, e1616.	2.5	230
14	Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. Journal of Neurochemistry, 2005, 93, 1030-1037.	3.9	229
15	Î±-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration. Journal of Neuroscience, 2003, 23, 3095-3099.	3.6	225
16	Caudoâ€rostral brain spreading of Î±â€synuclein through vagal connections. EMBO Molecular Medicine, 2013, 5, 1119-1127.	6.9	223
17	Dopamine and Lâ€dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB Journal, 2004, 18, 962-964.	0.5	220
18	Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiology of Disease, 2007, 25, 392-400.	4.4	217

#	ARTICLE	IF	CITATIONS
19	Environmental Factors in Parkinsonâ€™s Disease. NeuroToxicology, 2002, 23, 487-502.	3.0	213
20	Neurodegeneration by Activation of the Microglial Complement-Phagosome Pathway. Journal of Neuroscience, 2014, 34, 8546-8556.	3.6	192
21	Chapter 36: Astrocytes and Parkinson's disease. Progress in Brain Research, 1992, 94, 429-436.	1.4	166
22	Effect of 4-Hydroxy-2-nonenal Modification on Î±-Synuclein Aggregation. Journal of Biological Chemistry, 2007, 282, 5862-5870.	3.4	166
23	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochemical and Biophysical Research Communications, 1986, 137, 310-315.	2.1	165
24	Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Movement Disorders, 2000, 15, 459-466.	3.9	162
25	Brain-to-stomach transfer of Î±-synuclein via vagal preganglionic projections. Acta Neuropathologica, 2017, 133, 381-393.	7.7	148
26	Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochemical and Biophysical Research Communications, 1986, 137, 303-309.	2.1	143
27	Redox cycling of the herbicide paraquat in microglial cultures. Molecular Brain Research, 2005, 134, 52-56.	2.3	140
28	Î±-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra. PLoS ONE, 2010, 5, e12122.	2.5	138
29	Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Archives of Biochemistry and Biophysics, 1990, 282, 358-362.	3.0	134
30	Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiology of Aging, 2007, 28, 907-913.	3.1	127
31	Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular Î±-synuclein transfer. Journal of Clinical Investigation, 2019, 129, 3738-3753.	8.2	126
32	Nicotine reduces levodopaâ€induced dyskinesias in lesioned monkeys. Annals of Neurology, 2007, 62, 588-596.	5.3	124
33	LRRK2 kinase regulates Î±-synuclein propagation via RAB35 phosphorylation. Nature Communications, 2018, 9, 3465.	12.8	121
34	Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Experimental Neurology, 2007, 204, 619-630.	4.1	120
35	Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Research, 2000, 885, 283-288.	2.2	119
36	Effects of <scp>l</scp>â€dopa and other amino acids against paraquatâ€induced nigrostriatal degeneration. Journal of Neurochemistry, 2003, 85, 82-86.	3.9	119

#	Article	IF	Citations
37	Rapid ATP Loss Caused by Methamphetamine in the Mouse Striatum: Relationship Between Energy Impairment and Dopaminergic Neurotoxicity. Journal of Neurochemistry, 1994, 62, 2484-2487.	3.9	116
38	Oxidative and nitrative alphaâ€synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. Journal of Neurochemistry, 2013, 125, 491-511.	3.9	116
39	Metformin lowers Ser-129 phosphorylated Î±-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death and Disease, 2014, 5, e1209-e1209.	6.3	116
40	Mechanistic Approaches to Parkinson's Disease Pathogenesis. Brain Pathology, 2002, 12, 499-510.	4.1	115
41	Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of Neurochemistry, 2006, 98, 1866-1875.	3.9	113
42	Macrophage Antigen Complex-1 Mediates Reactive Microgliosis and Progressive Dopaminergic Neurodegeneration in the MPTP Model of Parkinsonâ€™s Disease. Journal of Immunology, 2008, 181, 7194-7204.	0.8	113
43	Î±-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiology of Disease, 2005, 20, 898-906.	4.4	111
44	Aging of the nigrostriatal system in the squirrel monkey. Journal of Comparative Neurology, 2004, 471, 387-395.	1.6	105
45	Serine 129 Phosphorylation Reduces the Ability of Î±-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo. Journal of Biological Chemistry, 2010, 285, 17648-17661.	3.4	105
46	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	1.7	104
47	Paraquat Neurotoxicity Is Mediated by a Bak-dependent Mechanism. Journal of Biological Chemistry, 2008, 283, 3357-3364.	3.4	102
48	Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Annals of Neurology, 2006, 60, 256-260.	5.3	99
49	Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage?. Annals of Neurology, 1992, 32, S111-S115.	5.3	98
50	The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Research, 1992, 572, 224-231.	2.2	89
51	Decreased hepatic glutathione in chronic alcoholic patients. Journal of Hepatology, 1986, 3, 1-6.	3.7	87
52	Role of Nitric Oxide in Methamphetamine Neurotoxicity: Protection by 7â€Nitroindazole, an Inhibitor of Neuronal Nitric Oxide Synthase. Journal of Neurochemistry, 1996, 67, 2443-2450.	3.9	86
53	Increased vulnerability of dopaminergic neurons in MPTPâ€lesioned interleukinâ€6 deficient mice. Journal of Neurochemistry, 2002, 83, 167-175.	3.9	85
54	Methionine oxidation stabilizes non-toxic oligomers of Î±-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 322-330.	3.8	85

#	Article	IF	Citations
55	Activation of the DNA damage response in vivo in synucleinopathy models of Parkinsonâ€™s disease. Cell Death and Disease, 2018, 9, 818.	6.3	85
56	Effects of 1-Methyl-4-Phenyl- 1,2,3,6-Tetrahydropyridine and 1 -Methyl-4-Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes. Journal of Neurochemistry, 1990, 54, 1295-1301.	3.9	84
57	Phosphorylation of Parkin at serine 65 is essential for its activation<i>in vivo</i>. Open Biology, 2018, 8, 180108.	3.6	81
58	Inhibition of Monoamine Oxidase Contributes to the Protective Effect of 7â€Nitroindazole Against MPTP Neurotoxicity. Journal of Neurochemistry, 1997, 69, 1771-1773.	3.9	78
59	Brain propagation of transduced Î±-synuclein involves non-fibrillar protein species and is enhanced in Î±-synuclein null mice. Brain, 2016, 139, 856-870.	7.6	78
60	Neuron-to-neuron Î±-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathologica Communications, 2015, 3, 13.	5.2	75
61	Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience, 2000, 98, 263-273.	2.3	73
62	Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Archives of Biochemistry and Biophysics, 1992, 295, 132-136.	3.0	72
63	Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of l-DOPA-treated monkeys. Brain Research, 1996, 738, 53-59.	2.2	71
64	Pathologic Modifications of Î±-Synuclein in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Squirrel Monkeys. Journal of Neuropathology and Experimental Neurology, 2008, 67, 793-802.	1.7	68
65	Relationships between intracellular vitamin E, lipid peroxidation, and chemical toxicity in hepatocytes. Toxicology and Applied Pharmacology, 1988, 93, 288-297.	2.8	66
66	Levodopa induces dyskinesias in normal squirrel monkeys. Annals of Neurology, 2001, 50, 254-257.	5.3	64
67	Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience, 2006, 141, 929-937.	2.3	64
68	Geneâ€“environment interactions in Parkinson's disease and other forms of parkinsonism. NeuroToxicology, 2010, 31, 598-602.	3.0	63
69	The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Research, 1990, 531, 242-252.	2.2	62
70	Increased Î±-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death and Disease, 2012, 3, e315-e315.	6.3	58
71	Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP. Trends in Pharmacological Sciences, 2017, 38, 541-555.	8.7	58
72	Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 49-63.	2.8	57

#	Article	IF	Citations
73	Toxicity of Redox Cycling Pesticides in Primary Mesencephalic Cultures. Antioxidants and Redox Signaling, 2005, 7, 649-653.	5.4	53
74	Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to Î±6Î²2* nAChRs. Journal of Neurochemistry, 2007, 100, 180-190.	3.9	52
75	The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain, 2017, 140, 2706-2721.	7.6	52
76	In vivo models of alpha-synuclein transmission and propagation. Cell and Tissue Research, 2018, 373, 183-193.	2.9	51
77	Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes. Biochemical and Biophysical Research Communications, 1988, 153, 734-740.	2.1	48
78	Novel Î±-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease. Experimental Neurology, 1998, 154, 684-690.	4.1	48
79	Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys. Neuroscience, 2005, 132, 409-420.	2.3	48
80	Nigrostriatal Dopaminergic Neurodegeneration in the Weaver Mouse Is Mediated via Neuroinflammation and Alleviated by Minocycline Administration. Journal of Neuroscience, 2006, 26, 11644-11651.	3.6	47
81	Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 770-777.	2.5	46
82	Î±-Synuclein Elevation in Human Neurodegenerative Diseases: Experimental, Pathogenetic, and Therapeutic Implications. Molecular Neurobiology, 2013, 47, 484-494.	4.0	45
83	tertâ€“butylhydroperoxideâ€"Induced toxicity in isolated hepatocytes: Contribution of thiol oxidation and lipid peroxidation. Journal of Biochemical Toxicology, 1986, 1, 13-22.	0.4	44
84	Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia, 1995, 15, 203-206.	4.9	44
85	Function and developmental origin of a mesocortical inhibitory circuit. Nature Neuroscience, 2015, 18, 872-882.	14.8	43
86	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	1.7	41
87	Decreased Î±-synuclein expression in the aging mouse substantia nigra. Experimental Neurology, 2009, 220, 359-365.	4.1	39
88	The selective Îº-opioid receptor agonist U50,488 reduces l-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Experimental Neurology, 2007, 205, 101-107.	4.1	38
89	Impaired Glutamate Clearance as a Consequence of Energy Failure Caused by MPP+ in Astrocytic Cultures. Toxicology and Applied Pharmacology, 1999, 158, 296-302.	2.8	37
90	Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience, 2002, 113, 213-220.	2.3	37

#	Article	IF	Citations
91	Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Research, 2007, 1140, 188-194.	2.2	36
92	VI. Studies on the mechanism of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine cytotoxicity in isolated hepatocytes. Life Sciences, 1987, 40, 741-748.	4.3	33
93	Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochemical and Biophysical Research Communications, 1987, 148, 153-160.	2.1	32
94	The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. Journal of Neuroscience Methods, 2005, 145, 159-166.	2.5	31
95	Induction of cell damage by menadione and benzo(a)-pyrene-3,6-quinone in cultures of adult rat hepatocytes and human fibroblasts. Toxicology Letters, 1985, 28, 37-47.	0.8	30
96	The biodisposition of MPP+ in mouse brain. Neuroscience Letters, 1989, 101, 83-88.	2.1	30
97	PCR Analysis of platelet mtDNA: Lack of specific changes in Parkinson's disease. Movement Disorders, 1993, 8, 74-82.	3.9	30
98	7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Research, 1999, 839, 41-48.	2.2	30
99	Sphingolipid changes in Parkinson L444P <i>GBA</i> mutation fibroblasts promote Î±-synuclein aggregation. Brain, 2022, 145, 1038-1051.	7.6	30
100	The role of environmental agents in Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 419-426.	0.8	29
101	Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes. Chemico-Biological Interactions, 1987, 62, 105-116.	4.0	27
102	Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia, 1992, 5, 48-55.	4.9	27
103	Nicotine administration reduces striatal MPP+ levels in mice. Brain Research, 2001, 917, 219-224.	2.2	27
104	Longâ€lasting pathological consequences of overexpressionâ€induced Î±â€synuclein spreading in the rat brain. Aging Cell, 2018, 17, e12727.	6.7	25
105	Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Experimental Neurology, 2006, 202, 434-440.	4.1	24
106	Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications. Current Protein and Peptide Science, 2009, 10, 476-482.	1.4	23
107	l-DOPA Does Not Cause Neurotoxicity in VMAT2 Heterozygote Knockout Mice. NeuroToxicology, 2002, 23, 611-619.	3.0	20
108	Role of Astrocytes in MPTP Metabolism and Toxicity. Annals of the New York Academy of Sciences, 1992, 648, 219-228.	3.8	19

#	Article	IF	Citations
109	Pesticides and Parkinson's Disease: Current Experimental and Epidemiological Evidence. Advances in Neurotoxicology, 2017, 1, 83-117.	1.9	15
110	Autoradiographic analysis of N-methyl-d-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Levodopa treatment. Neuroscience, 2000, 99, 697-704.	2.3	14
111	Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology, 2005, 48, 398-405.	4.1	14
112	Evidence of oxidative stress in young and aged DJâ€•1â€•deficient mice. FEBS Letters, 2013, 587, 1562-1570.	2.8	14
113	The transcription factor BCL11A defines distinct subsets of midbrain dopaminergic neurons. Cell Reports, 2021, 36, 109697.	6.4	14
114	Comparative toxicity and antioxidant activity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes. Archives of Biochemistry and Biophysics, 1987, 255, 14-18.	3.0	11
115	Autoradiographic analysis of dopamine receptor-stimulated [35S]GTPÎ³S binding in rat striatum. Brain Research, 2000, 885, 133-136.	2.2	11
116	Inhibition of microglial Î²-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. Journal of Neuroinflammation, 2021, 18, 220.	7.2	11
117	Paraquat Exposure Reduces Nicotinic Receptor-Evoked Dopamine Release in Monkey Striatum. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 124-129.	2.5	10
118	Letter regarding: â€œParaquat: The Red Herring of Parkinson's Disease Researchâ€• Toxicological Sciences, 2008, 103, 215-216.	3.1	10
119	MPTP-Induced ATP Loss in Mouse Brain. Annals of the New York Academy of Sciences, 1992, 648, 306-308.	3.8	9
120	Blood lactate in Parkinson's disease. Annals of Neurology, 1991, 29, 342-343.	5.3	8
121	Acute exposure to organochlorine pesticides does not affect striatal dopamine in mice. Neurotoxicity Research, 2001, 3, 537-543.	2.7	8
122	Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Experimental Neurology, 2003, 183, 173-179.	4.1	8
123	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain. Brain Research, 1994, 647, 249-254.	2.2	6
124	Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinsonâ€™s disease. Cell Death and Differentiation, 2021, 28, 1720-1732.	11.2	6
125	Diethyldithiocarbamate and disulfiram inhibit MPP+ and dopamine uptake by striatal synaptosomes. European Journal of Pharmacology, 1989, 166, 23-29.	3.5	5
126	Mesenchymal stromal SB623 cell implantation mitigates nigrostriatal dopaminergic damage in a mouse model of Parkinson's disease. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 1835-1843.	2.7	5

#	Article	IF	Citations
127	Role of Active Oxygen in Paraquat and 1-Methyl-4-phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Cytotoxicity. , 1988, 49, 795-801.		5
128	The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic Î±-Synuclein Spread in Rodent Models of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1463-1478.	2.8	2
129	Commentary on â€˜Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)â€™. Toxicology Letters, 1989, 48, 117-119.	0.8	1
130	Paraquat-induced Neurodegeneration: a Model of Parkinson's Disease Risk Factors. , 2008, , 207-217.		1
131	Overview of Neurodegenerative Disorders and Susceptibility Factors in Neurodegenerative Processes. , 2015, , 197-210.		1
132	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. International Review of Movement Disorders, 2021, 2, 155-191.	0.1	0